Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line?

Karyopharm finally got its much-needed first commercial approval for a drug that has stirred up safety concerns—and suffered plenty of speed bumps—along the way. Now the company must cope with a limited FDA nod, and with a brand-new marketing chief to boot.